HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amyris Making Headway In Fermentation-Derived Cannabinoids; CBD Could Hit Market In Early 2020

Executive Summary

Synthetic biology firm Amyris has shipped to partner Lavvan its first cannabinoid produced via genetically engineered yeast. While Amyris’ announcement does not identify the specific cannabinoid, Lavvan leadership indicated in March 2019 that fermentation-derived CBD would be first to market, representing potential purity and value benefits compared with CBD extracted from the cannabis plant.

You may also be interested in...

Amyris Inks Deal For Third Clean Beauty Brand; Inter Parfums’ Third Quarter; Beauty News In Brief

Amyris plans to launch new Rose Inc. cosmetics in the third quarter of 2021. “We believe cosmetics to be the next opportunity for us to transform to clean,” says Amyris CEO John Melo. News in brief.

Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues

The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.

CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up

Attorneys are warning CBD product marketers to be on guard for litigation challenging the authenticity of their claims, the safety of their products and other aspects of their businesses. So far, suits of this nature have been limited in the US, but the few known cases could be harbingers of a larger wave to come.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts